A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient) in High-risk Soft Tissue Sarcoma.

Trial Profile

A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient) in High-risk Soft Tissue Sarcoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms NOPASS
  • Most Recent Events

    • 20 Jan 2017 This trial was discontinued in Germany (end date: 2016-12-31), according to European Clinical Trials Database.
    • 30 Jan 2014 According to ClinicalTrials.gov record, planned End Date changed from 1 Nov 2016 to 1 Jun 2018.
    • 28 May 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-003745-18).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top